Klivira
Request demo

Navigating Medicare Nucala Prior Authorization

Managing Medicare Nucala prior authorization can introduce significant administrative complexity for revenue cycle teams. Klivira provides intelligent automation to streamline these critical workflows, ensuring timely patient access to essential biologic therapies.

Nucala (mepolizumab), an Interleukin-5 (IL-5) antagonist, is a targeted biologic therapy for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). For Medicare beneficiaries, securing prior authorization (PA) for Nucala involves navigating distinct pathways depending on whether the patient has Original Medicare or a Medicare Advantage (MA) plan, and whether the drug falls under the medical or pharmacy benefit.

Understanding Nucala (Mepolizumab) and its Indications

Nucala is prescribed for patients with persistent symptoms despite standard therapy, often characterized by elevated eosinophil counts. As a high-cost biologic, Nucala is consistently a target for prior authorization across various payer types, including Medicare, to ensure medical necessity and appropriate utilization per clinical guidelines.

Medicare's Prior Authorization Landscape for Nucala

The approach to prior authorization for Nucala varies significantly within Medicare. Original Medicare (Parts A and B) has a limited scope for prior authorization, primarily managed by Medicare Administrative Contractors (MACs). In contrast, Medicare Advantage (Part C) plans, administered by private insurers, typically have broader prior authorization requirements mirroring commercial plans, often including extensive utilization management for specialty drugs like Nucala.

Nucala Prior Authorization under Medicare Part D

For Nucala dispensed through a pharmacy benefit, prior authorization falls under Medicare Part D. Part D plans, operated by commercial insurers as private contractors, administer pharmacy PA according to CMS-approved plan formularies and step-therapy protocols. Klivira integrates with these Part D plans, leveraging NCPDP SCRIPT and other ePA channels to automate submission and status checks for Nucala.

Prior Authorization for Nucala under Original Medicare (Part B)

If Nucala is administered in a clinic or outpatient setting and covered under the Medicare Part B medical benefit, prior authorization requirements are typically more limited under Original Medicare. Where PA does apply, submissions route through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. MACs such as Noridian, NGS, WPS, Palmetto, FCSO, and Novitas handle these medical benefit PA requests, often for specific services or demonstrations.

Policy and Coverage Determinations for Nucala

Coverage for Nucala under Medicare is governed by National Coverage Determinations (NCDs) published by CMS and Local Coverage Determinations (LCDs) issued by individual MACs. Klivira's platform incorporates NCD and LCD-aware policy logic, ensuring that prior authorization submissions for Nucala are aligned with the most current coverage criteria and jurisdictional specifics, including necessary citations and effective dates.

Streamlining Medicare Nucala PA with Klivira

Klivira's prior authorization automation platform simplifies the complex process for Nucala under Medicare. For Original Medicare, our MAC-aware routing handles per-jurisdiction submission specifics. For Medicare Advantage and Part D plans, Klivira connects directly to payer portals and ePA channels, reducing manual data entry, accelerating turnaround times, and minimizing the administrative burden on your staff.

Frequently asked questions

Is Nucala always subject to prior authorization under Medicare?

Prior authorization for Nucala is highly common. While Original Medicare has limited PA scope, Medicare Advantage and Part D plans almost universally require prior authorization for Nucala due to its specialty drug status and cost, necessitating a demonstration of medical necessity.

How does prior authorization for Nucala differ between Original Medicare and Medicare Advantage plans?

Under Original Medicare, Nucala PA (if applicable under Part B) is handled by Medicare Administrative Contractors (MACs) with limited scope. Medicare Advantage plans, however, are managed by private insurers and typically have more extensive PA requirements, similar to commercial plans, often involving specific formularies and utilization management criteria.

Which entities handle Nucala prior authorization for Original Medicare?

For Nucala covered under Original Medicare's medical benefit (Part B), prior authorization requests are routed through the responsible Medicare Administrative Contractor (MAC) for the provider's jurisdiction. Examples of MACs include Noridian, NGS, WPS, Palmetto, FCSO, and Novitas.

What are the primary policy sources for Nucala coverage under Medicare?

Coverage policies for Nucala under Medicare are primarily derived from National Coverage Determinations (NCDs) issued by CMS and Local Coverage Determinations (LCDs) published by the specific Medicare Administrative Contractor (MAC) for a given region.

Can Klivira automate Nucala prior authorizations for both Medicare Part B and Part D?

Yes, Klivira automates Nucala prior authorizations across both Medicare Part B (where applicable, routing through MACs) and Medicare Part D (connecting to commercial insurers and PBMs). Our platform adapts to the specific submission channels and policy requirements for each Medicare segment.

Related coverage

Other nucala prior authorization by payer

Other nucala prior authorization by specialty

Ready to automate prior auth for this drug?

See how Klivira automates prior authorizations for your team.

Request a demo